Lamotrigine and Stevens-Johnson Syndrome Prevention

Area of Science:

• Pharmacogenomics
• Immunology
• Dermatology

Background:

• Stevens-Johnson Syndrome (SJS) is a rare, life-threatening mucocutaneous reaction.
• Medications like antiepileptics are common triggers, with lamotrigine being a frequent culprit.
• Genetic factors, such as specific human leukocyte antigen (HLA) genotypes, increase susceptibility in certain populations.

Purpose of the Study:

• To explore the role of HLA genotypes in lamotrigine-induced SJS.
• To inform clinical practice regarding lamotrigine reintroduction after SJS.
• To highlight the importance of genetic screening for SJS prevention.

Main Methods:

• Review of existing literature on SJS etiology and lamotrigine.
• Analysis of HLA associations with drug-induced SJS in various ethnic groups.
• Examination of lamotrigine re-challenge protocols and risk factors for recurrence.

Main Results:

• Specific HLA subtypes (e.g., HLAB*15:02, HLAB*31:01, HLA-B*44:03) are linked to increased SJS risk with lamotrigine.
• Lamotrigine reintroduction is possible with careful dosing and consideration of initial rash severity.
• Mild initial rash, not occurring within 4 weeks, indicates lower recurrence risk for re-challenge.

Conclusions:

• Genetic screening for HLA subtypes is crucial before initiating lamotrigine, as recommended by the FDA.
• Understanding pharmacogenetic predispositions can mitigate the risk of severe adverse drug reactions like SJS.
• Careful patient selection and management strategies are essential for safe lamotrigine therapy.